Go Pro
NASDAQ:OSRH

OSR Q1 2025 Earnings Report

OSR logo
$0.25 -0.03 (-9.75%)
Closing price 04:00 PM Eastern
Extended Trading
$0.22 -0.03 (-11.60%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OSR EPS Results

Actual EPS
-$1.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OSR Revenue Results

Actual Revenue
$0.76 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OSR Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OSR Earnings Headlines

Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.tc pixel
OSR Holdings Stock Price History
See More OSR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OSR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OSR and other key companies, straight to your email.

About OSR

OSR (NASDAQ:OSRH) Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

View OSR Profile